Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Hemophilia A patients with self-described problem joints were found to have worse clinical outcomes, with more pain, in a new study.

A Lincoln nurse who specialises in looking after patients with blood disorders has been named Nurse of the Year. Alison ...

For centuries, hemophilia was a dangerous genetic disorder with no treatment. Children with hemophilia often didn't make it to adulthood, since a bump or fall could cause massive internal bleeding.

Federal funding ensures that hemophilia treatment centers can properly care for those with bleeding disorders, columnist Jennifer Lynne says.

The data showed that Mim8 was well-tolerated and efficacious in children with haemophilia A with and without inhibitors. In part one of the FRONTIER3 study, participants with haemophilia A received ...

We are a year out from her birth and still monitoring for any symptoms. Hemophilia A has been a challenge, to say the least, but with every day and every experience I endure, I learn more and more ...

This kind of AD inheritance is like that of quintessential genetic diseases, such as hemophilia, or classic traits of textbook genetics, such as the color of Gregor Mendel's garden peas. The familial ...

The two drugs are directed at different indications, however, as Alhemo is indicated for use in haemophilia A and B patients with inhibitors. There are some 7,000 known rare diseases in the world ...

CSL and uniQure’s gene therapy for haemophilia B has been approved by the European Commission, ushering in a new era of therapy for patients with the bleeding disorder in the EU. The therapy has ...